Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.48 | N/A | +82.72% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.48 | N/A | +82.72% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding the company's performance. They emphasized their commitment to innovation and growth.
Management expressed satisfaction with the EPS results despite not providing revenue figures.
They highlighted ongoing efforts in research and development as a key focus moving forward.
This earnings report indicates that Gilead Sciences has performed well in terms of earnings per share, significantly exceeding expectations. However, the lack of revenue data and guidance leaves some uncertainty about the company's overall financial health. Investors will need to wait for further information to gauge the stock's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KIMBERLY CLARK CORP
Apr 21, 2014